Aerosol delivery of recombinant human DNase I: In vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer

Jeremy C. Johnson, J. Clifford Waldrep, Jennifer Guo, Rajiv Dhand

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BACKGROUND: Inhaled recombinant human DNase I (rhDNase) improves clearance of viscoelastic secretions in patients with cystic fibrosis. Because of their portability, newer-generation vibrating-mesh nebulizers offer greater convenience for the patient, but their efficiency in delivering rhDNase has not been determined. METHODS: We compared a newer-generation vibratingmesh nebulizer (Omron MicroAir) to a Pari LC+ with the Pari ProNeb Ultra compressor (a commonly employed rhDNase administration system). With the Next Generation Pharmaceutical Impactor, we determined aerosol particle distribution. We also measured mass output efficiency, nebulization time, and mass of rhDNase that deposited on a filter during simulated breathing. RESULTS: The mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of aerosol from the MicroAir (MMAD 4.3 μm, GSD 2.8 μm) was equivalent to that from the Pari LC+ (MMAD 4.2 μm, GSD 2.7 μm). During simulated breathing the MicroAir had a higher total mass output efficiency (88%) than the Pari LC+ (68%) (P < .001), and total nebulization time was shorter with the MicroAir (6.1 min vs 7.2 min, P = .03). When nebulized to dryness, the mass of rhDNase delivered to the filter was comparable with the MicroAir (1.30 ± 0.4 mg) and Pari LC+ (1.21 ± 0.05 mg). CONCLUSION: The MicroAir could be employed as a portable nebulizer for rhDNase therapy in patients with cystic fibrosis.

Original languageEnglish (US)
Pages (from-to)1703-1708
Number of pages6
JournalRespiratory Care
Volume53
Issue number12
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Nebulizers and Vaporizers
Deoxyribonuclease I
Aerosols
Cystic Fibrosis
Respiration
In Vitro Techniques
dornase alfa
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Aerosol delivery of recombinant human DNase I : In vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer. / Johnson, Jeremy C.; Waldrep, J. Clifford; Guo, Jennifer; Dhand, Rajiv.

In: Respiratory Care, Vol. 53, No. 12, 01.12.2008, p. 1703-1708.

Research output: Contribution to journalArticle

Johnson, Jeremy C. ; Waldrep, J. Clifford ; Guo, Jennifer ; Dhand, Rajiv. / Aerosol delivery of recombinant human DNase I : In vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer. In: Respiratory Care. 2008 ; Vol. 53, No. 12. pp. 1703-1708.
@article{ace13e7f5a184717a51d3d5eb9411d4b,
title = "Aerosol delivery of recombinant human DNase I: In vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer",
abstract = "BACKGROUND: Inhaled recombinant human DNase I (rhDNase) improves clearance of viscoelastic secretions in patients with cystic fibrosis. Because of their portability, newer-generation vibrating-mesh nebulizers offer greater convenience for the patient, but their efficiency in delivering rhDNase has not been determined. METHODS: We compared a newer-generation vibratingmesh nebulizer (Omron MicroAir) to a Pari LC+ with the Pari ProNeb Ultra compressor (a commonly employed rhDNase administration system). With the Next Generation Pharmaceutical Impactor, we determined aerosol particle distribution. We also measured mass output efficiency, nebulization time, and mass of rhDNase that deposited on a filter during simulated breathing. RESULTS: The mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of aerosol from the MicroAir (MMAD 4.3 μm, GSD 2.8 μm) was equivalent to that from the Pari LC+ (MMAD 4.2 μm, GSD 2.7 μm). During simulated breathing the MicroAir had a higher total mass output efficiency (88{\%}) than the Pari LC+ (68{\%}) (P < .001), and total nebulization time was shorter with the MicroAir (6.1 min vs 7.2 min, P = .03). When nebulized to dryness, the mass of rhDNase delivered to the filter was comparable with the MicroAir (1.30 ± 0.4 mg) and Pari LC+ (1.21 ± 0.05 mg). CONCLUSION: The MicroAir could be employed as a portable nebulizer for rhDNase therapy in patients with cystic fibrosis.",
author = "Johnson, {Jeremy C.} and Waldrep, {J. Clifford} and Jennifer Guo and Rajiv Dhand",
year = "2008",
month = "12",
day = "1",
language = "English (US)",
volume = "53",
pages = "1703--1708",
journal = "Respiratory Care",
issn = "0020-1324",
publisher = "Daedalus Enterprises Inc.",
number = "12",

}

TY - JOUR

T1 - Aerosol delivery of recombinant human DNase I

T2 - In vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer

AU - Johnson, Jeremy C.

AU - Waldrep, J. Clifford

AU - Guo, Jennifer

AU - Dhand, Rajiv

PY - 2008/12/1

Y1 - 2008/12/1

N2 - BACKGROUND: Inhaled recombinant human DNase I (rhDNase) improves clearance of viscoelastic secretions in patients with cystic fibrosis. Because of their portability, newer-generation vibrating-mesh nebulizers offer greater convenience for the patient, but their efficiency in delivering rhDNase has not been determined. METHODS: We compared a newer-generation vibratingmesh nebulizer (Omron MicroAir) to a Pari LC+ with the Pari ProNeb Ultra compressor (a commonly employed rhDNase administration system). With the Next Generation Pharmaceutical Impactor, we determined aerosol particle distribution. We also measured mass output efficiency, nebulization time, and mass of rhDNase that deposited on a filter during simulated breathing. RESULTS: The mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of aerosol from the MicroAir (MMAD 4.3 μm, GSD 2.8 μm) was equivalent to that from the Pari LC+ (MMAD 4.2 μm, GSD 2.7 μm). During simulated breathing the MicroAir had a higher total mass output efficiency (88%) than the Pari LC+ (68%) (P < .001), and total nebulization time was shorter with the MicroAir (6.1 min vs 7.2 min, P = .03). When nebulized to dryness, the mass of rhDNase delivered to the filter was comparable with the MicroAir (1.30 ± 0.4 mg) and Pari LC+ (1.21 ± 0.05 mg). CONCLUSION: The MicroAir could be employed as a portable nebulizer for rhDNase therapy in patients with cystic fibrosis.

AB - BACKGROUND: Inhaled recombinant human DNase I (rhDNase) improves clearance of viscoelastic secretions in patients with cystic fibrosis. Because of their portability, newer-generation vibrating-mesh nebulizers offer greater convenience for the patient, but their efficiency in delivering rhDNase has not been determined. METHODS: We compared a newer-generation vibratingmesh nebulizer (Omron MicroAir) to a Pari LC+ with the Pari ProNeb Ultra compressor (a commonly employed rhDNase administration system). With the Next Generation Pharmaceutical Impactor, we determined aerosol particle distribution. We also measured mass output efficiency, nebulization time, and mass of rhDNase that deposited on a filter during simulated breathing. RESULTS: The mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of aerosol from the MicroAir (MMAD 4.3 μm, GSD 2.8 μm) was equivalent to that from the Pari LC+ (MMAD 4.2 μm, GSD 2.7 μm). During simulated breathing the MicroAir had a higher total mass output efficiency (88%) than the Pari LC+ (68%) (P < .001), and total nebulization time was shorter with the MicroAir (6.1 min vs 7.2 min, P = .03). When nebulized to dryness, the mass of rhDNase delivered to the filter was comparable with the MicroAir (1.30 ± 0.4 mg) and Pari LC+ (1.21 ± 0.05 mg). CONCLUSION: The MicroAir could be employed as a portable nebulizer for rhDNase therapy in patients with cystic fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=61449495105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61449495105&partnerID=8YFLogxK

M3 - Article

C2 - 19025706

AN - SCOPUS:61449495105

VL - 53

SP - 1703

EP - 1708

JO - Respiratory Care

JF - Respiratory Care

SN - 0020-1324

IS - 12

ER -